Brentuximab Vedotin in Combination with Bendamustine for Patients with Relapsed/Refractory Hodgkin Lymphoma After Front-Line Therapy


Brentuximab Vedotin in Combination with Bendamustine for Patients with Relapsed/Refractory Hodgkin Lymphoma After Front-Line Therapy
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
LaCasce A et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. Proc ASH 2014;Abstract 293.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.